Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $3.71 Analyst target: $3.67 Upside: -1.16%
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products to improve the lives of patients with genetically defined diseases in areas of high unmet medical need in the United States. The company is headquartered in Cambridge, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.